BeiGene Acquires an Exclusive Global License from Ensem Therapeutics for its Experimental Oral CDK2 Inhibitor EXT-197
Shots:
- BeiGene announces the exclusive worldwide license to develop & commercialise Ensem Therapeutics' investigational oral CDK2 inhibitor EXT-197 for cancer
- The financial terms of the deal remained undisclosed but are expected to reach ~$1.33B if Ensem meets all the development, regulatory & commercial milestones. Additionally, Ensem is entitled to receive undisclosed tiered royalties
- EXT-197, developed as an oral inhibitor of the CDK2 protein which is responsible for regulation of cell cycle & is hyperactivated during cancer
Ref: BeiGene | Image: BeiGene
Related News:- Johnson & Johnson Report Results from P-III ENSEMBLE Trial for COVID-19 Vaccine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
